Congenital generalized lipodystrophy type 1
Other Names for this Disease
- Berardinelli-Seip congenital lipodystrophy type 1
- Brunzell syndrome, AGPAT2-related
Medical ProductsThe medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.
(Amylin Pharmaceuticals, LLC)
The FDA has approved this product to be used in this manner.
|Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.|
|More Information about this product||Drug Information Portal|